Cite

HARVARD Citation

    Abreu, M. et al. (n.d.). DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. Journal of Crohn's and colitis. pp. S113-S115. [Online]. 
  
Back to record